Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Genetics of Paroxysmal Dyskinesia: Novel Variants Corroborate the Role of KCNA1 in Paroxysmal Dyskinesia and Highlight the Diverse Phenotypic Spectrum of KCNA1- and SLC2A1-Related Disorders

Josua Kegele*, Johanna Krüger, Mahmoud Koko, Lara Lange, Ana Victoria Marco Hernandez, Francisco Martinez, Alexander Münchau, Holger Lerche, Stephan Lauxmann

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Paroxysmal dyskinesias (PxD) are rare movement disorders with characteristic episodes of involuntary mixed hyperkinetic movements. Scientific efforts and technical advances in molecular genetics have led to the discovery of a variety of genes associated with PxD; however, clinical and genetic information of rarely affected genes or infrequent variants is often limited. In our case series, we present two individuals with PxD including one with classical paroxysmal kinesigenic dyskinesia, who carry new likely pathogenic de novo variants in KCNA1 (p.Gly396Val and p.Gly396Arg). The gene has only recently been discovered to be causative for familial paroxysmal kinesigenic dyskinesia. We also provide genetic evidence for pathogenicity of two newly identified disease-causing variants in SLC2A1 (p.Met96Thr and p.Leu231Pro) leading to paroxysmal exercise-induced dyskinesia. Since clinical information of carriers of variants in known disease-causing genes is often scarce, we encourage to share clinical data of individuals with rare or novel (likely) pathogenic variants to improve disease understanding.

OriginalspracheEnglisch
Aufsatznummer701351
ZeitschriftFrontiers in Neurology
Jahrgang12
ISSN1664-2295
DOIs
PublikationsstatusVeröffentlicht - 08.07.2021

Fördermittel

The research was supported by the German Federal Ministry for Education and Research (BMBF, IonNeurONet: 01GM1105A, TreatION 01GM1907A), the EuroEPINOMICS Programme, and the European Reference Network—Rare Neurological Diseases (ERN—RND; Project ID No. 739510). AVM holds a grant CM19/00181 (Instituto de Salud Carlos III-Río Hortega). We thank the patients and family members that have contributed samples for the purpose of this study. C. Hengsbach and A. Maisch are thanked for data organization and sample logistics. Funding. The research was supported by the German Federal Ministry for Education and Research (BMBF, IonNeurONet: 01GM1105A, TreatION 01GM1907A), the EuroEPINOMICS Programme, and the European Reference Network?Rare Neurological Diseases (ERN?RND; Project ID No. 739510). AVM holds a grant CM19/00181 (Instituto de Salud Carlos III-R?o Hortega).

TrägerTrägernummer
Bundesministerium für Bildung und ForschungTreatION 01GM1907A, 01GM1105A, 739510
Instituto de Salud Carlos III

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
    • Zentren: Zentrum für Seltene Erkrankungen (ZSE)

    DFG-Fachsystematik

    • 2.23-06 Molekulare und zelluläre Neurologie und Neuropathologie
    • 2.23-07 Klinische Neurologie, Neurochirurgie und Neuroradiologie

    Zitieren